Hemostemix (CVE:HEM) Reaches New 12-Month Low at $0.01

Shares of Hemostemix Inc (CVE:HEM) reached a new 52-week low on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 911000 shares. The stock had previously closed at C$0.02.

The firm has a market cap of $6.02 million and a price-to-earnings ratio of -0.48. The stock’s fifty day moving average is C$0.03 and its two-hundred day moving average is C$0.04.

About Hemostemix (CVE:HEM)

Hemostemix Inc, a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient's own blood, a relatively non-invasive source of therapeutic cells. The company's lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia.

Read More: Why Invest in High-Yield Dividend Stocks?

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.